IQ services in its Core Lab as part of its expanded IQ-Analytics Platform, which includes Amyloid IQ and DaT IQ. Invicro scientists, Drs. Alex Whittington and Roger Gunn, are co-authors of this pioneering research which describes the development and validation of Tau IQ as a superior method for the quantitative analysis of Tau PET biomarker data in Alzheimer’s Disease clinical trials. Tau IQ demonstrated a 2-3-fold increase in power over currently available methods and promises to increase the value of tau imaging endpoints for decision making in clinical trials. “This groundbreaking approach will have a significant impact on clinical imaging trials in Alzheimer’s Disease (AD). The improved signals provided by Tau